Gujarat-based maker of animal vaccines, feed supplements and therapeutics for poultry, livestock and pets.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 193 | 220 | 251 | 271 | 283 | 306 | 329 | 352 |
| Borrowings | 121 | 105 | 228 | 274 | 244 | 213 | 214 | 195 |
| Other Liabilities | 65 | 78 | 74 | 116 | 126 | 126 | 124 | 123 |
| Total Liabilities | 387 | 411 | 562 | 670 | 662 | 653 | 675 | 678 |
| AssetsFixed Assets | 143 | 133 | 237 | 259 | 240 | 233 | 247 | 411 |
| CWIP | 74 | 109 | 82 | 149 | 171 | 183 | 182 | 9 |
| Investments | 0 | 0 | 21 | 25 | 30 | 34 | 37 | 43 |
| Other Assets | 170 | 169 | 222 | 237 | 221 | 203 | 209 | 215 |
| Total Assets | 387 | 411 | 562 | 670 | 662 | 653 | 675 | 678 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 47 | 37 | 58 | 9 | 24 | 48 | 65 | 64 |
| Cash from Investing | -21 | -73 | -42 | -117 | -77 | -22 | -20 | -18 |
| Cash from Financing | 3 | 19 | -18 | 112 | 42 | -26 | -52 | -49 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 24 | -36 | 17 | -87 | -54 | 24 | 44 | 47 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (51.0×) and current (38.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 18.1% growth and a 38× exit, ₹2076 only delivers your return if you pay ₹2,124. The price is currently baking in 18% growth.
EPS grows 18.1%/yr for 5 years, then fades to 6% over 2, exits at 38×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 18.1% | 64.35 |
| FY28 | 18.1% | 76.00 |
| FY29 | 18.1% | 89.76 |
| FY30 | 18.1% | 106.00 |
| FY31 | 18.1% | 125.19 |
| FY32 | 12.1% ·fade | 140.27 |
| FY33 | 6.0% ·fade | 148.69 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.